Neurotoxicity due to imipenem/cilastatin in patients on continuous ambulatory peritoneal dialysis.
M
M
Rivera
M
M
Crespo
J L
JL
Teruel
R
R
Marcén
J
J
Ortuño
D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001424:Bacterial Infections / Q000188:drug therapy / Q000209:etiology; D015377:Cilastatin / Q000009:adverse effects*; D006801:Humans; D015378:Imipenem / Q000009:adverse effects*; D007676:Kidney Failure, Chronic / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009207:Myoclonus / Q000139:chemically induced*; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects*; D010538:Peritonitis / Q000188:drug therapy / Q000209:etiology; D011480:Protease Inhibitors / Q000009:adverse effects; D011537:Pruritus / Q000139:chemically induced; D013845:Thienamycins / Q000009:adverse effects
D000900:Anti-Bacterial Agents; D011480:Protease Inhibitors; D013845:Thienamycins; D015377:Cilastatin; D015378:Imipenem